Global X Data Center & Digital Infra ETF vs Cassava Sciences Inc — how do they compare? Global X Data Center & Digital Infra ETF trades at $27.97 (market cap $2.04B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Global X Data Center & Digital Infra ETF is far larger — about 51.8× Cassava Sciences Inc's market cap, and Global X Data Center & Digital Infra ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 15 Days and Cassava Sciences Inc for 37 Days on average.
| DTCR | FLNA | |
|---|---|---|
Market Cap | $2.04B | $39.40M |
Volume | 899,532 | 759,018 |
Sector | Sector/Thematic | Health |
52-Week High | $32.46 | $4.64 |
52-Week Low | $19.73 | $0.68 |
Typical Hold Time | 15 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.
Read more on DTCR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →